ZA200201903B - Use of H1 antagonist and a safe steriod to treat eye conditions. - Google Patents

Use of H1 antagonist and a safe steriod to treat eye conditions. Download PDF

Info

Publication number: ZA200201903B
Authority: ZA; South Africa
Prior art keywords: antagonist; composition; safe; emedastine; loteprednol
Prior art date: 1999-11-18

Application number

ZA200201903A

Other languages

English (en)

Inventor

John M Yanni

Original Assignee

Alcon Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-18

Filing date

2002-03-07

Publication date

2003-05-28

2002-03-07 Application filed by Alcon Inc filed Critical Alcon Inc

2003-05-28 Publication of ZA200201903B publication Critical patent/ZA200201903B/en

Links

239000000938 histamine H1 antagonist Substances 0.000 title claims 12
239000000203 mixture Substances 0.000 claims description 28
150000003431 steroids Chemical class 0.000 claims description 26
FXEMVMUWTJUWJB-DKOUAETMSA-N Dexamethasone beloxil Chemical compound O=C([C@]1(O)[C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)COCC1=CC=CC=C1 FXEMVMUWTJUWJB-DKOUAETMSA-N 0.000 claims description 11
229960000325 emedastine Drugs 0.000 claims description 10
KBUZBQVCBVDWKX-UHFFFAOYSA-N emedastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 KBUZBQVCBVDWKX-UHFFFAOYSA-N 0.000 claims description 10
229960001798 loteprednol Drugs 0.000 claims description 10
YPZVAYHNBBHPTO-MXRBDKCISA-N loteprednol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)OCCl)[C@@H]4[C@@H]3CCC2=C1 YPZVAYHNBBHPTO-MXRBDKCISA-N 0.000 claims description 10
239000005557 antagonist Substances 0.000 claims description 9
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 5
229960004114 olopatadine Drugs 0.000 claims description 5
JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 claims description 5
CXFNDBLYDZRFQL-UHFFFAOYSA-N 1-(2-ethoxyethyl)-2-[[4-(4-pyrazol-1-ylbutyl)piperazin-1-yl]methyl]benzimidazole Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1CN(CC1)CCN1CCCCN1C=CC=N1 CXFNDBLYDZRFQL-UHFFFAOYSA-N 0.000 claims description 3
DPPDPATYPQFYDL-UHFFFAOYSA-N 2-[2-(dimethylamino)ethyl]-4-methyl-2,3-dihydropyrido[3,2-f][1,4]oxazepine-5-thione Chemical compound O1C(CCN(C)C)CN(C)C(=S)C2=CC=CN=C21 DPPDPATYPQFYDL-UHFFFAOYSA-N 0.000 claims description 3
MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 claims description 3
ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims description 3
ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 claims description 3
241000124008 Mammalia Species 0.000 claims description 3
HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 claims description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-L Oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 claims description 3
GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 claims description 3
229960004574 azelastine Drugs 0.000 claims description 3
229960000725 brompheniramine Drugs 0.000 claims description 3
ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 claims description 3
229960001803 cetirizine Drugs 0.000 claims description 3
229960003291 chlorphenamine Drugs 0.000 claims description 3
SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 claims description 3
229960002881 clemastine Drugs 0.000 claims description 3
YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 claims description 3
FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 claims description 3
229960004958 ketotifen Drugs 0.000 claims description 3
229960001120 levocabastine Drugs 0.000 claims description 3
ZCGOMHNNNFPNMX-KYTRFIICSA-N levocabastine Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)[C@@H]2CC[C@@](CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-KYTRFIICSA-N 0.000 claims description 3
229960003088 loratadine Drugs 0.000 claims description 3
JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims description 3
229950003360 mapinastine Drugs 0.000 claims description 3
229960000582 mepyramine Drugs 0.000 claims description 3
YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 claims description 3
229960005042 mequitazine Drugs 0.000 claims description 3
238000000034 method Methods 0.000 claims description 3
229960001487 rimexolone Drugs 0.000 claims description 3
QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 claims description 3
229950003786 rocastine Drugs 0.000 claims description 3
229960000351 terfenadine Drugs 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
208000002205 allergic conjunctivitis Diseases 0.000 description 14
238000009472 formulation Methods 0.000 description 9
206010018258 Giant papillary conjunctivitis Diseases 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
208000018464 vernal keratoconjunctivitis Diseases 0.000 description 7
230000000699 topical effect Effects 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
229940054534 ophthalmic solution Drugs 0.000 description 4
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000004410 intraocular pressure Effects 0.000 description 3
239000002997 ophthalmic solution Substances 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000000739 antihistaminic agent Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
206010003645 Atopy Diseases 0.000 description 1
208000002177 Cataract Diseases 0.000 description 1
239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000003266 anti-allergic effect Effects 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
206010069664 atopic keratoconjunctivitis Diseases 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000004406 elevated intraocular pressure Effects 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
239000003885 eye ointment Substances 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
230000007803 itching Effects 0.000 description 1
206010023332 keratitis Diseases 0.000 description 1
201000010666 keratoconjunctivitis Diseases 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
238000011328 necessary treatment Methods 0.000 description 1
229940100655 ophthalmic gel Drugs 0.000 description 1
229940069265 ophthalmic ointment Drugs 0.000 description 1
229940100654 ophthalmic suspension Drugs 0.000 description 1
230000035515 penetration Effects 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
-1 such as Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
229960000707 tobramycin Drugs 0.000 description 1
238000011282 treatment Methods 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)

ZA200201903A 1999-11-18 2002-03-07 Use of H1 antagonist and a safe steriod to treat eye conditions. ZA200201903B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US16619499P	1999-11-18	1999-11-18

Publications (1)

Publication Number	Publication Date
ZA200201903B true ZA200201903B (en)	2003-05-28

Family

ID=22602196

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200201903A ZA200201903B (en)	1999-11-18	2002-03-07	Use of H1 antagonist and a safe steriod to treat eye conditions.

Country Status (12)

Country	Link
US (1)	US6649602B1 (pl)
EP (1)	EP1242090A4 (pl)
CN (1)	CN1376066A (pl)
AU (1)	AU772406B2 (pl)
BR (1)	BR0015647A (pl)
CA (1)	CA2380532A1 (pl)
HK (1)	HK1047699A1 (pl)
MX (1)	MXPA02005007A (pl)
PL (1)	PL355101A1 (pl)
TR (1)	TR200201322T2 (pl)
WO (1)	WO2001035963A1 (pl)
ZA (1)	ZA200201903B (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19954516A1 (de) *	1999-11-12	2001-05-17	Boehringer Ingelheim Int	Epinastin-haltige Lösungen
TWI231759B (en)	2001-06-27	2005-05-01	Alcon Inc	Olopatadine formulations for topical administration
US7977376B2 (en)	2001-06-27	2011-07-12	Novartis Ag	Olopatadine formulations for topical nasal administration
ES2258175T3 (es) *	2001-12-05	2006-08-16	Alcon, Inc.	Utilizacion de un antagonista de h1 y remixolona como esteroide inofensivo para el tratamiento de la rinitis.
PL373433A1 (pl)	2002-08-30	2005-08-22	Altana Pharma Ag	Zastosowanie kombinacji cyklezonidu i śrdoków przeciwhistaminowych do leczenia alergicznego nieżytunosa
BR0316203A (pt) *	2002-11-12	2005-10-04	Alcon Inc	Uso de um agente antialérgico e um esteróide para tratar rinite alérgica
KR20050092429A (ko) *	2003-01-22	2005-09-21	니찌방 가부시기가이샤	안질환 치료용 경피 흡수형 제제, 그 사용, 및 안질환치료약의 눈의 국소 조직으로의 이행 방법
US20050239745A1 (en) *	2004-03-03	2005-10-27	Ophthalmic Research Associates, Inc.	Novel topical ophthalmic formulations
US20060089384A1 (en) *	2004-10-25	2006-04-27	Minno George E	Ophthalmic compositions and methods of using the same
WO2006047418A1 (en) *	2004-10-25	2006-05-04	Alimera Sciences, Inc.	Ophthalmic compositions and methods of using the same
DK2486942T3 (en)	2004-11-24	2019-01-28	Meda Pharmaceuticals Inc	COMPOSITIONS CONTAINING AZELASTINE AND PROCEDURES FOR USING IT
US20070020330A1 (en)	2004-11-24	2007-01-25	Medpointe Healthcare Inc.	Compositions comprising azelastine and methods of use thereof
US8758816B2 (en)	2004-11-24	2014-06-24	Meda Pharmaceuticals Inc.	Compositions comprising azelastine and methods of use thereof
WO2006097458A1 (en) *	2005-03-15	2006-09-21	Nycomed Gmbh	Novel combination
US20110104159A1 (en) *	2006-09-11	2011-05-05	Rohrs Brian R	Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy
US20110105559A1 (en) *	2006-09-11	2011-05-05	Rohrs Brian R	Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy
PL2061444T3 (pl) *	2006-09-11	2011-09-30	Bausch & Lomb	Kompozycje i sposoby leczenia, traktowania, kontrolowania, redukowania, łagodzenia lub zapobiegania alergii
EP2222299B1 (en) *	2007-11-19	2011-11-23	Bausch & Lomb Incorporated	Use of levocabastine for modulating generation of pro-inflammatory cytokines
US8569273B2 (en)	2009-03-17	2013-10-29	Aciex Therapeutics, Inc.	Ophthalmic formulations of cetirizine and methods of use
WO2010107525A1 (en) *	2009-03-17	2010-09-23	Aciex Therapeutics, Inc.	Ophthalmic formulations of ketotifen and methods of use
CA2755679C (en)	2009-03-17	2017-09-12	Aciex Therapeutics, Inc.	Ophthalmic formulations of cetirizine and methods of use
US20130023520A1 (en) *	2011-07-24	2013-01-24	Amir Sahba Jalali	Anaesthetic eye solution and method of use
WO2013061269A1 (en) *	2011-10-26	2013-05-02	Micro Labs Limited	Combinations of loteprednol and olopatadine for the treatment of ocular allergies
EP3061501A1 (en)	2015-02-27	2016-08-31	Rottapharm Ltd.	Composition for the treatment of acne
EP3117825A1 (en)	2015-07-16	2017-01-18	Rottapharm S.p.A.	Oral formulation comprising berberine and morus alba extract

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5223493A (en)	1984-12-28	1993-06-29	Alcon Laboratories, Inc.	Anti-inflammatory compounds for ophthalmic use
US5149694A (en)	1988-03-09	1992-09-22	Alcon Laboratories, Inc.	Combination of tobramycin and dexamethasone for topical ophthalmic use
US5192780A (en)	1989-12-18	1993-03-09	Alcon Laboratories, Inc.	Methods using antiallergics and antihistamines
US5668133A (en)	1992-12-09	1997-09-16	Alcon Laboratories, Inc.	Ophthalmic compositions comprising emedastine and methods for their use
US5540930A (en) *	1993-10-25	1996-07-30	Pharmos Corporation	Suspension of loteprednol etabonate for ear, eye, or nose treatment
US5420120A (en)	1993-12-17	1995-05-30	Alcon Laboratories, Inc.	Anti-inflammatory glucocorticoid compounds for topical ophthalmic use

2000
- 2000-10-26 US US10/069,851 patent/US6649602B1/en not_active Expired - Lifetime
- 2000-10-26 EP EP00978273A patent/EP1242090A4/en not_active Withdrawn
- 2000-10-26 CA CA002380532A patent/CA2380532A1/en not_active Abandoned
- 2000-10-26 BR BR0015647-7A patent/BR0015647A/pt not_active Application Discontinuation
- 2000-10-26 PL PL00355101A patent/PL355101A1/pl not_active Application Discontinuation
- 2000-10-26 AU AU46101/01A patent/AU772406B2/en not_active Ceased
- 2000-10-26 TR TR2002/01322T patent/TR200201322T2/xx unknown
- 2000-10-26 CN CN00813426A patent/CN1376066A/zh active Pending
- 2000-10-26 MX MXPA02005007A patent/MXPA02005007A/es active IP Right Grant
- 2000-10-26 HK HK02108832.3A patent/HK1047699A1/zh unknown
- 2000-10-26 WO PCT/US2000/029436 patent/WO2001035963A1/en not_active Ceased
2002
- 2002-03-07 ZA ZA200201903A patent/ZA200201903B/en unknown

Also Published As

Publication number	Publication date
CA2380532A1 (en)	2001-05-25
US6649602B1 (en)	2003-11-18
TR200201322T2 (tr)	2002-11-21
EP1242090A4 (en)	2004-02-11
CN1376066A (zh)	2002-10-23
WO2001035963A1 (en)	2001-05-25
HK1047699A1 (zh)	2003-03-07
EP1242090A1 (en)	2002-09-25
MXPA02005007A (es)	2004-08-12
BR0015647A (pt)	2002-07-16
AU4610101A (en)	2001-05-30
PL355101A1 (pl)	2004-04-05
AU772406B2 (en)	2004-04-29

Publication	Publication Date	Title
US6649602B1 (en)	2003-11-18	Use of an H1 antagonist and a safe steroid to treat eye conditions
AU594427B2 (en)	1990-03-08	Anti-inflammatory compounds for opthalmic use
US20100041671A1 (en)	2010-02-18	Methods for treating glaucoma
CA2502437A1 (en)	2004-05-06	Method and composition containing latanoprost for treating ocular hypertension and glaucoma
KR20020050273A (ko)	2002-06-26	에피나스틴 함유 액제
JPS6322021A (ja)	1988-01-29	眼圧制御剤
KR101103141B1 (ko)	2012-01-04	Ｒｈｏ 키나아제 억제제와 β 차단약으로 이루어진 녹내장치료제
AU2002366567B2 (en)	2006-11-16	Use of an H1 antagonist and a safe steroid to treat rhinitis
AU636685B2 (en)	1993-05-06	Compositions of antiallergics and antihistamines and methods for their use
KR100776577B1 (ko)	2007-11-16	점안제
US5441958A (en)	1995-08-15	Ophthalmic compositions comprising emedastine and methods for their use
US5668133A (en)	1997-09-16	Ophthalmic compositions comprising emedastine and methods for their use
US20050009902A1 (en)	2005-01-13	Remedies for pruritus
US20040097486A1 (en)	2004-05-20	Use of an H1 antagonist and a safe steroid to treat eye conditions
US6071875A (en)	2000-06-06	TGFα for the treatment of ocular hypertension and glaucoma
US5612364A (en)	1997-03-18	Substantially pure apraclonidine
AU734789B2 (en)	2001-06-21	Use of a combination of carbonic anhydrease inhibitors and prostaglandins for treating glaucoma
CZ294314B6 (cs)	2004-11-10	Topické oftalmické léčivo
US4623664A (en)	1986-11-18	Oil suspended phenylephrine
US5654335A (en)	1997-08-05	Topical use of ethyl ethacrynate for glaucoma treatment
WO1998014193A1 (en)	1998-04-09	The use of a substance p antagonist for the manufacture of a medicament for the treatment of ocular pain
US5457126A (en)	1995-10-10	Use of lodoxamide to treat ophthalmic allergic conditions
JPH08231400A (ja)	1996-09-10	イフェンプロジルを必須成分とする眼圧降下剤
WO1998056379A1 (en)	1998-12-17	Compositions and methods for treating glaucoma
EP0406210B1 (en)	1995-09-27	Ophthalmic composition